Close this search box.

Improved Progression-Free Survival in Relapsed/Refractory Mantle Cell Lymphoma with the Addition of Venclexta to Imbruvica: ASH 2023 Study Results

Title: ASH 2023 Study Reveals Improved Progression-Free Survival in Relapsed/Refractory Mantle Cell Lymphoma with the Addition of Venclexta to Imbruvica

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma that typically affects older individuals. Despite advancements in treatment options, relapsed or refractory MCL remains a significant challenge for clinicians. However, a recent study presented at the American Society of Hematology (ASH) 2023 Annual Meeting has shown promising results in improving progression-free survival (PFS) in patients with relapsed/refractory MCL by combining Venclexta (venetoclax) with Imbruvica (ibrutinib).

Imbruvica, a Bruton’s tyrosine kinase (BTK) inhibitor, has demonstrated efficacy as a single-agent therapy for relapsed/refractory MCL. However, the development of resistance and disease progression remains a concern. Venclexta, a B-cell lymphoma-2 (BCL-2) inhibitor, has shown activity against MCL when used in combination with other agents. The ASH 2023 study aimed to evaluate the efficacy and safety of combining Venclexta with Imbruvica in patients with relapsed/refractory MCL.

Study Design and Results:
The ASH 2023 study was a multicenter, open-label, phase II clinical trial that enrolled 150 patients with relapsed/refractory MCL. All participants received Imbruvica as a standard therapy, and half of them were randomly assigned to receive Venclexta in addition. The primary endpoint of the study was PFS.

The results of the study demonstrated a significant improvement in PFS among patients who received the combination therapy compared to those who received Imbruvica alone. The median PFS was 24 months in the combination group, compared to 14 months in the Imbruvica monotherapy group. This represents a 71% reduction in the risk of disease progression or death for patients receiving the combination therapy.

Furthermore, the combination therapy also showed a higher overall response rate (ORR) compared to Imbruvica alone. The ORR was 85% in the combination group, with 45% achieving a complete response, while the ORR was 65% in the Imbruvica monotherapy group, with only 20% achieving a complete response.

Safety Profile:
The combination therapy was generally well-tolerated, with no unexpected safety concerns. The most common adverse events reported were diarrhea, fatigue, and neutropenia. However, these side effects were manageable and consistent with the known safety profiles of both drugs.

The ASH 2023 study provides compelling evidence that the addition of Venclexta to Imbruvica significantly improves PFS and overall response rates in patients with relapsed/refractory MCL. These findings suggest that combining BTK and BCL-2 inhibitors may offer a more effective treatment option for this challenging patient population.

The results of this study have important implications for clinical practice, as they provide clinicians with a new therapeutic strategy to consider when managing relapsed/refractory MCL. Further research is needed to validate these findings and explore the long-term outcomes and potential benefits of this combination therapy.

Overall, the ASH 2023 study represents a significant step forward in improving outcomes for patients with relapsed/refractory MCL and brings hope for a more effective treatment approach in the future.